The global candidiasis drugs market is estimated to grow at a CAGR of ~6% over the forecast period, i.e., 2022 – 2030. Candida is a yeast, that causes infection in the mucosal layer. The growth of the market can be attributed to the growing cases of yeast infection across the world, backed by poor immunity, sanitation practices, and others. The increasing health awareness, availability of anti-fungal drugs, and growing investment in development of new drugs, is estimated to boost the market growth. Candida is usually present inside the skin, in parts lined with mucous, such as the mouth, throat, gut, and vagina, without causing any problems. Infections are caused when the yeast grows out of control, due to high amount of sugar in blood, high humidity, or poor hygiene. Diabetes is a major factor for candidiasis infection, as raised blood sugar promotes yeast activation. The growing incidences of diabetes is estimated to boost the market growth over the forecast period. According to the report by the World Health Organization (WHO), 422 million people worldwide suffer from diabetes, in countries of all income levels, and around 1.6 million deaths are directly attributed to it each year.
Get more information on this report: Download Sample PDF
The market is segmented by disease type into oral, vaginal, cutaneous, invasive, and others, out of which, the vaginal segment is anticipated to hold the notable share in the global candidiasis drugs market over the forecast period on the back of the increasing cases of vaginal candidiasis, backed by lack of sexual health awareness and hygiene amongst individuals, especially in the middle and low-income countries. According to the data by the Center for Disease Control and Prevention (CDC), about 20% women who have candida in the vagina, do not notice any symptoms.
Vaginal candidiasis is not a sexually transmitted disease. It is caused due to poor hygiene, hot and humid environment around the vulva, sharing toilets, and even due to drinking less amount of water. Mild infections are often overlooked, due to the embarrassment and taboo associated with diseases in the private parts, resulting in severe infection and even hospitalization. This is a major factor expected to drive the segment growth. Pregnancy and hormonal contraceptives are also a major cause of candidiasis in the vagina.
According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.
On the basis of geographical analysis, the global candidiasis drugs market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in the Asia Pacific region is estimated to witness noteworthy growth over the forecast period on the back of increasing prevalence of candidiasis, backed by the climatic conditions that promote yeast infection. Moreover, lack of proper sanitation in the region, and lower rate of health awareness, especially in rural parts of the developing countries, is estimated to boost the regional market growth. The market in the Middle East and Africa region is also estimated to witness significant growth owing to the lack of hygiene and sanitation, and hot & humid climate of the region.
The market in the North America region is anticipated to gain the largest market share throughout the forecast period owing to the constantly rising cases of candidiasis, especially invasive candidiasis in the region. As per a report by the CDC, approximately 25,000 cases of candidemia are recorded in the United States each year. The high prevalence of diabetes is one of the primary factors for the increasing candidiasis cases in the region.
Get more information on this report: Download Sample PDF
The global candidiasis drugs market is further classified on the basis of region as follows:
Our in-depth analysis of the global candidiasis drug market includes the following segments:
FREQUENTLY ASKED QUESTIONS
The increasing cases of candidiasis is estimated to boost the market growth.
The market is anticipated to attain a CAGR of ~6% over the forecast period, i.e., 2022 – 2030.
Lack of health awareness amongst people is estimated to hamper the market growth.
The market in the North America region is estimated to provide more business opportunities over the forecast period, owing to the higher prevalence of the disease in the region.
The major players in the market are Pfizer Inc., Glenmark Pharmaceuticals, Merck KGaA, Novartis AG, Sanofi-aventis Groupe, Teva Pharmaceutical Industries Ltd., and others.
The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.
The market is segmented by disease type, drug type, end-user, and by region.
The hospital segment is anticipated to hold largest market size over the forecast period and display significant growth opportunities.
Select License Type
Direct access to analyst to help you understand the market in a better way to handle your critical question
Citing your business specific requirement our consultant would assist you ensuring targeted goal is achieved
Get 10% free customization